Cutaneous amyloidosis is a general term for a group of diseases with common features and different clinical manifestations caused by abnormal deposition of amyloid proteins outside the cells of tissues and organs. This group of diseases can be divided into systemic and restrictive according to the extensiveness of the area involved, and systemic can be divided into primary, secondary, genetic and senile types; restrictive can be divided into cutaneous, nodular, secondary, endocrine and genetic. The etiology of the disease is unclear. Primary cases often have skin damage, secondary ones can be secondary to chronic inflammation and tumors, mainly involving substantial organs without skin damage, and some cutaneous amyloidosis is genetically related and can be combined in certain syndromes. The disease can be treated with oral antihistamines, such as Avionics capsules. It can also be treated topically with strong glucocorticoid preparations, phototherapy, or carboplatinum ointment, but with limited efficacy. Nodularity can be treated with surgical excision, electrocautery, cryotherapy, and carbon dioxide laser therapy, but it is prone to recurrence, and there is no satisfactory outcome for primary ones.